An Open-Label, Single-Sequence Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
Latest Information Update: 23 Apr 2021
At a glance
- Drugs Milvexian (Primary) ; Rifampicin (Primary)
- Indications Stroke; Thrombosis; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 05 Jan 2017 Status changed from not yet recruiting to completed.
- 10 Nov 2016 New trial record